Thr198
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr198  -  NPM1 (mouse)

Site Information
VKKsVRdtPAKNAQK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448515

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 6 , 8 ) , mutation of modification site ( 7 , 9 , 10 ) , phospho-antibody ( 5 , 7 , 9 , 10 ) , western blotting ( 5 , 7 , 9 , 10 )
Disease tissue studied:
brain cancer ( 2 , 3 , 4 ) , neuroendocrine cancer ( 2 , 3 , 4 )
Relevant cell line - cell type - tissue:
32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 6 ) , 32Dcl3 (myeloid) ( 6 ) , 3T3 (fibroblast) ( 9 ) , brain ( 2 , 3 , 4 ) , fibroblast-embryo [CDK2 (mouse), homozygous knockout] ( 5 ) , fibroblast-embryo [CDK4 (mouse), homozygous knockout] ( 5 ) , fibroblast-embryo [p53 (mouse), homozygous knockout] ( 5 ) , fibroblast-skin ( 9 , 10 ) , Hepa 1-6 (epithelial) ( 8 ) , MEF (fibroblast) ( 7 )

Upstream Regulation
Regulatory protein:
CDK2 (mouse) ( 5 ) , CDK4 (mouse) ( 5 ) , p53 (mouse) ( 5 )
Kinases, in vitro:
CDK2 (human) ( 10 )
Treatments:
aphidicolin ( 7 ) , nocodazole ( 7 ) , seliciclib ( 7 ) , serum ( 5 , 7 , 9 )

Downstream Regulation
Effects of modification on NPM1:
intracellular localization ( 10 ) , molecular association, regulation ( 9 )
Effects of modification on biological processes:
cell cycle regulation ( 9 ) , cytoskeletal reorganization ( 5 , 9 ) , RNA splicing, altered ( 10 )
Induce interaction with:
RNA ( 10 ) , ROCK2 (mouse) ( 9 )

References 

1

Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250
27841257   Curated Info

2

Guo A (2011) CST Curation Set: 12728; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

3

Guo A (2011) CST Curation Set: 12729; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

4

Guo A (2011) CST Curation Set: 12730; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

5

Adon AM, et al. (2010) Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol 30, 694-710
19933848   Curated Info

6

Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140   Curated Info

7

Brady SN, et al. (2009) Nucleophosmin protein expression level, but not threonine 198 phosphorylation, is essential in growth and proliferation. Oncogene 28, 3209-20
19561638   Curated Info

8

Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46
18846507   Curated Info

9

Ma Z, et al. (2006) Interaction between ROCK II and nucleophosmin/B23 in the regulation of centrosome duplication. Mol Cell Biol 26, 9016-34
17015463   Curated Info

10

Tarapore P, et al. (2006) Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre-mRNA processing. FEBS Lett 580, 399-409
16376875   Curated Info